SCHEMBL9892876

SCHEMBL9892876

CC(C)(C)OC(=O)N1CC[C@H]1C(=O)Nc1nc(C(C)(C)C)cs1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.52
LMNA P02545 4/20 0.48
NPSR1 Q6W5P4 4/20 0.48
CFD P00746 1/20 0.48
NPC1 O15118 8/20 0.47
RAB9A P51151 7/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
TAS1R2 Q8TE23 1/20 0.46
TSHR P16473 2/20 0.46
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPK1 P28482 2/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
CNR2 P34972 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9107269 0.93 L3MBTL1 (0.61) ATAD2L3MBTL1LMNANPSR1CFD
SCHEMBL9107258 0.93 L3MBTL1 (0.61) ATAD2L3MBTL1LMNANPSR1CFD
SCHEMBL9892892 0.83 CNR2 (0.53) ATAD2L3MBTL1LMNANPSR1NPC1
SCHEMBL9892868 0.83 TMIGD3 (0.50) ATAD2L3MBTL1LMNANPSR1NPC1
SCHEMBL9892928 0.82 SMN1; SMN2 (0.56) L3MBTL1LMNANPSR1NPC1RAB9A
SCHEMBL20458202 0.79 ATAD2 (0.47) ATAD2L3MBTL1LMNANPSR1CFD
SCHEMBL31197943 0.79 L3MBTL1 (0.46) L3MBTL1LMNANPSR1NPC1RAB9A
SCHEMBL9892800 0.79 RAB9A (0.52) L3MBTL1LMNANPSR1NPC1RAB9A
SCHEMBL31198011 0.79 L3MBTL1 (0.46) L3MBTL1LMNANPSR1NPC1RAB9A
SCHEMBL9892918 0.79 LMNA (0.50) L3MBTL1LMNANPSR1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 ATAD2 1461/4885L3MBTL1 4866/4885LMNA 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.